ATHA Athira Pharma

Athira Pharma to Participate in Upcoming June Conferences

Athira Pharma to Participate in Upcoming June Conferences

BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences:

Jefferies Healthcare Conference

Fireside Chat on Wednesday, June 7, 2023, at 8:30 a.m. ET in New York

Goldman Sachs 44th Annual Global Healthcare Conference

Presentation on Wednesday, June 14, 2023, at 8:40 a.m.PT in Dana Point, California

Live webcasts of the Jefferies fireside chat and Goldman Sachs presentation can be accessed from the Investors section of the Athira website at . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to provide rapid cognitive improvement and alter the course of neurological diseases with its novel mechanism of action. Athira is currently advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies and amyotrophic lateral sclerosis (ALS). For more information, visit . You can also follow Athira on , , and @athirapharma on .

Investor & Media Contact:

Julie Rathbun

Athira Pharma



206-769-9219



EN
31/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athira Pharma

 PRESS RELEASE

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline an...

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and bus...

 PRESS RELEASE

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective E...

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association’s 35th International...

 PRESS RELEASE

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipelin...

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2024, and provided recent pipeline and business updates. “We are pleased to be contin...

 PRESS RELEASE

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial...

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD) will be presented at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) taking place Oct...

 PRESS RELEASE

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of...

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical trial with completion expected by year end 2024 and commencement of dosing of ALS patients expected in 2025  Company announces cost containment measures in alignment with focus on advancing ATH-1105 BOTHELL, Wash., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch